Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

By R. Herbrecht, D. Denning, T. Patterson, J. Bennett, R. Greene, J. Oestmann, W. Kern, K. Marr, P. Ribaud, O. Lortholary and 12 more. New England Journal of Medicine, 2002

3,179 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/a586fdad7ea0c9d23b0057f3dda8a4bfba3f355b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Infectious Diseases

Citations in the corpus

Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism (2008, neutral): “Voriconazole was superior to amphotericin B for the treatment of invasive aspergillosis and has become the primary choice to treat this condition [2].”
Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. (2009, background): “[12] in the original validation trial of voriconazole for the”
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “trial comparing voriconazole to AmB deoxycholate followed by other licensed therapy [348] found that GMI at week 1 was significantly lower than baseline GM in the eventual 12-week re-”
Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management (2005, neutral): “extrapolation from studies of Aspergillus infection (52), which”
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (2008, background): “Indeed, the definitions were modified to allow enrollment of similar cases into clinical trials, because they are considered to represent likely invasive fungal disease even without supporting mycological evidence [2, 16].”
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). (2007, methodology): “amphotericin B deoxycholate in a recent trial [6].”
Aspergillus Infections in Transplant Recipients (2005, background): “The study was an open, randomized comparison of voriconazole and conventional amphotericin (116).”
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, background): “The one randomized trial for invasive aspergillosis demonstrated a trend toward improvement of CNS aspergillosis in patients who were treated with voriconazole [115].”
Resistance to Antifungal Agents: Mechanisms and Clinical Impact (2008, methodology): “Recent therapeutic trials in invasive mycoses have found that overall (empirical and directed) treatment success rates have ranged from 32% to 74% [83, 97, 98], indicating that in vitro susceptibility testing alone is not sufﬁcient to predict clinical success.”
Voriconazole treatment for less-common, emerging, or refractory fungal infections. (2003, background): “Compared with amphotericin B (AmB), it has a favorable outcome for the treatment of patients with primary invasive aspergillosis [7, 8].”
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2016, background): “Importantly, very few studies had a large number of patients with a mycological documentation.(40,41,50) As shown by the 2 post-hoc analyses, survival was substantially lower in mycologically-documented infections compared to possible cases.”
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. (2010, background): “Therapy for presumed aspergillosis (for cases with typical infiltrates on CT) could consist of either voriconazole or liposomal amphotericin B [I, A] [29, 30].”
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. (2004, background): “Moreover, voriconazole is superior in efficacy to deoxycholate amphotericin B in the primary treatment of IA [17].”